人脑膜瘤VEGF的表达和微血管检测及临床意义

目的探讨人脑膜瘤血管内皮细胞生长因子(VEGF)的表达和微血管数量(MVQ)与肿瘤良恶性程度的关系。方法用免疫组织化学染色方法检测手术切除石蜡包埋的36例脑膜瘤(良性27例,恶性9例)组织中的VEGF蛋白表达情况与MVQ数量,显微镜下观察其阳性细胞数和阳性血管数。结果①良、恶性脑膜瘤组织中均有VEGF和MVQ表达,且主要表达于肿瘤细胞的胞浆和血管内皮细胞胞膜中;良、恶性脑膜瘤VEGF表达的阳性率分别为77.8%、100%,有显著性差异(P<0.05);VEGF表达阳性的MVQ平均值(47.6±8.5)高于阴性组(24.3±7.9),差异有统计学意义(P <0.01)。②VEGF的表达与MVQ值相关(r =0.75,P <0.01)。结论VEGF在脑膜瘤血管生成中起重要作用,能促进脑膜瘤血管的形成;VEGF和MVQ与脑膜瘤良、恶性程度明显相关,可作为脑膜瘤病理诊断的补充指标之一,并为脑膜瘤的基因治疗提供依据。     

脑膜瘤中EGFR和PTEN的表达及意义

目的探讨脑膜瘤组织中表皮生长因子受体（EGFR）和人10号染色体上缺失的磷酸酶和张力蛋白类似物（PTEN）表达的相互关系及意义。方法应用免疫组织化学SP法对60例脑膜瘤标本的EGFR和PTEN表达进行检测与分析。结果在90％（54／60）的脑膜瘤中EGFR过表达，非典型脑膜瘤及间变性脑膜瘤中EGFR的染色强度明显高于典型脑膜瘤（P〈0．05）；PTEN在各病理级别脑膜瘤中的阳性率为100％，而且各病理级别脑膜瘤中PTEN的染色强度无统计学差别（P〉0．05）。结论EGFR的表达强度与脑膜瘤的恶性程度有关，抑癌基因PTEN在脑膜瘤中未见缺失，可能与脑膜瘤的发生、发展无关。     

Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival

Chromogenic in situ hybridization (CISH) was used to detect amplification of the epidermal growth factor receptor (EGFR) gene in tissue microarrays of tumours derived from 287 patients with grade II-IV diffuse astrocytomas. Amplification was found in 32% of the tumours with a highly significant association with histological grade (4% in grade II, 21% in grade III and 39% in grade IV; P < 0.001). Amplification of the EGFR gene was more common in primary than in secondary glioblastomas (41%vs. 16%, P = 0.033). Overexpression of EGFR mRNA and protein (wild-type and vIII variant) was found to correlate with EGFR gene amplification (P = 0.028, P = 0.035 and P = 0.014 respectively), but wild-type EGFR protein was also frequently overexpressed in tumours without EGFR gene amplification. Patients with older age (P < 0.001) and tumours with lack of p53 overexpression (P = 0.03) and higher apoptosis rate (P < 0.001) had significantly more EGFR gene amplifications than their counterparts. No such correlation with apoptosis was found in glioblastomas. The survival of patients with EGFR gene-amplified grade III tumours was significantly shorter than in those with grade III non-amplified tumours (P = 0.03). No such difference was noted in glioblastomas (grade IV tumours). Our data verify the central role of EGFR in the pathobiology of astrocytic tumours, and highlight the advantages of CISH as a simple and practical assay to screen for EGFR gene amplification in astrocytic tumours.     

人脑膜瘤IGF-1表达及其意义

目的探讨人脑膜瘤组织中胰岛素样生长因子-1（IGF-1）的表达及其意义。方法收集人脑膜瘤标本110例,其中WHOⅠ、Ⅱ和Ⅲ级分别为70、22和18例;另收集正常脑膜标本12例作为对照组。采用免疫组化染色法分析IGF-1、增殖细胞核抗原（PCNA）和第Ⅷ因子相关抗原（FⅧ-RAg）表达情况。结果脑膜瘤组织中IGF-1、PCNA、FⅧ-RAg表达水平较正常硬脑膜组织明显增高（P〈0.05）;随着脑膜瘤WHO级别增高,IGF-1、PCNA、FⅧ-RAg表达水平亦明显增高（P〈0.05）。同一级别脑膜瘤组织中,IGF-1、PCNA、FⅧ-RAg两两之间均呈显著正相关（P〈0.05）。结论人脑膜瘤组织中IGF-1的表达强弱与脑膜瘤血管生成、细胞增殖活性有关。     

Cell‐adhesion molecules in human meningiomas: correlation with clinical and morphological data

Integrins form a family of cell adhesion molecules. CD44 glycoproteins are found in a wide variety of isoforms; the most common, CD44s (standard) is widely distributed, and functions as an adhesion molecule. In this study, we have investigated immunohistochemically the distribution of some VLA integrins (α2, α5 and α6 chains of β1 integrins) and CD44s in 44 meningioma specimens and normal arachnoid villi. Meningiomas were of meningothelial (16), transitional (13) and fibroblastic (15) subtypes. There were 13 grade I, 19 grade II and 12 grade III (27%). Immunoprecipitates were quantified by image analysis and correlated with clinical (age, sex, location) and morphological data (histological subtypes and grades). VLA α5 chain was expressed by normal arachnoid villi (mainly cap cells) and by 42 out of 44 meningioma specimens. Expression was lower in fibroblastic meningiomas (P=0.02). VLA α2 and α6 chains were not observed in normal arachnoid villi. VLA α2 was expressed by 15 meningiomas, VLA α6 by 10. Interestingly, meningiomas expressing either VLA α2 or α6 were usually of grade III (P≤0.05). CD44s was found on various parts of arachnoid villi and in all meningiomas although expression was higher in meningothelial and transitional than in fibroblastic (P≤0.001). These results show that VLA α5 and CD44s are widely expressed by arachnoid villi and meningiomas, in contrast to VLA α2 and VLA α6. It was noted that high grade meningiomas (III) express VLA α2 and α6 suggesting that changes in integrin pattern expression are a feature of these meningiomas. Moreover, strong CD44s expression characterizes meningothelial and transitional meningiomas. Previous studies have shown that high NCAM expression is a feature of fibroblastic meningiomas whereas meningothelial and transitional meningiomas expressed mainly E-Cadherin, and that polysialylated NCAM expression was restricted to high grade meningiomas. Taken together these features suggest that each cell adhesion molecule has a characteristic pattern of expression according to meningioma subtype and grade. No correlation was seen between integrins and CD44s expression and clinical data.     

中国人胶质瘤中表皮生长因子受体基因的扩增及对患者预后的影响

目的：了解国人胶质瘤中表皮生长因子受体基因（EGFR）的扩增情况及对患者预后的影响。方法：使用半定量的Differential PCR方法对113例福尔马林固定-石蜡包埋（FFEP）胶质瘤标本内的EGFR基因扩增情况进行了检测；对其中的83例进行了生存分析研究。结果：113例胶质瘤中存在EGFR基因扩增的有26例，其中低度恶性组中仅占3.5％，而在高度恶性组中占42.1％。生存分析显示：EGFR基因扩增对患者预后并无显著影响，而起病年龄、肿瘤病理分级、肿瘤生长部位及起病症状为失语对患者术后生存期有显著影响。结论：恶性胶质瘤中存在着较为广泛的EGFR基因扩增，但EGFR基因的扩增与胶质瘤患者预后之间并不存在显著关联。     

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptor flt-1 in microcystic meningiomas

We investigated the immunohistochemical expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and of its endothelial cell receptor flt-1 in relationship to microcyst formation in meningiomas. Expression of VPF/VEGF was studied in 60 meningiomas (6 microcystic, 38 partially microcystic and 16 with no microcystic areas) and 30 meningiomas from these three subgroups were evaluated for flt-1 expression. VPF/VEGF immunoreactivity was mainly observed in vessel endothelium. Positive vessels were present in 75% (33/44) of meningiomas with any amount of microcystic pattern and in 38% (6/16) of the solid meningiomas (P < 0.02). Densities and percentages of both VPF/VEGF-positive and flt-1-positive vessels were higher in meningiomas with microcystic areas than in solid meningiomas (P≤ 0.002). The 6 microcystic meningiomas showed the highest densities and percentages of both VPF/VEGF-positive (P≤ 0.0002) and flt-1-positive vessels (P≤ 0.01). Vessel expression of VPF/VEGF and flt-1 were positively correlated (r≥ 0.75, P < 0.0001). A strong positive correlation between VPF/VEGF-positive vessel density and proportion of microcystic pattern in all 60 specimens was found (r = 0.75, P < 0.0001). We conclude that accumulation of flt-1-bound VPF/VEGF on endothelial cells of meningiomas is associated with microcyst formation that leads to the histologic appearance of microcystic meningiomas. Received: 18 January 1999 / Revised, accepted: 31 March 1999     

Chronic treatment with scopolamine and physostigmine changes nerve growth factor (NGF) receptor density and NGF content in rat brain

Nerve growth factor (NGF) and NGF receptors were measured in cortex and hippocampus of rats treated with drugs affecting cholinergic neurotransmission. High (K_d= 0.045nM) and low (K_d= 21nM) affinity¹²⁵I-NGF binding sites were present in both cortical and hippocampal membranes with hippocampus containing higher numbers of both sites than cortex. Chronic treatment of rats with the muscarinic receptor antagonist scopolamine (5 mg/kg, twice daily) decreased the density of high- and low-affinity sites by 50–90% in cortical and hippocampal membranes. These changes were seen after 7 days, but not 3 days, of scopolamine treatment. Chronic infusion of physostigmine (1 mg/kg/day) using minipumps increased the number of high- and low-affinity sites in cortex 3- and 6-fold, respectively. The changes in receptor-binding parameters induced by physostigmine were transient as they were evident after 3 days of treatment, but returned to control levels after 7 days. NGF content in cortex and hippocampus was reduced by about 50% following 7, but not 3, days of chronic physostigmine infusion. In contrast, scopolamine treatment failed to change NGF levels in the cholinergic neuronal target regions but it decreased NGF content in the septal area. The content of NGF mRNA in the cortex measured by Northern blot analysis failed to change following either scopolamine or physostigmine treatment. The results suggest that levels of NGF and NGF receptors in the target regions of cholinergic neurons are regulated by the extent of cholinergic neurotransmitter activity.     

Epidermal growth factor receptor expression and activation in neuroendocrine tumours

Epidermal growth factor receptor (EGFR) is expressed in many cancers and is associated with poor prognosis. EGFR activation pathways have been well characterised using tumour cell lines and are known to involve EGFR activation through autophosphorylation. Phosphorylation of downstream signalling molecules, such as ERK1/2 (extra-cellular regulated kinase 1 and 2) and PKB/Akt (protein kinase B), leads to enhanced tumour cell survival and proliferation. Although EGFR expression has been determined in neuroendocrine tumour tissue, its activation and subsequent effects on the downstream signalling molecules, ERK1/2 and Akt, have not been studied. We therefore planned to determine the role of EGFR in neuroendocrine tumours (NETs) by determining its pattern of expression and activation, and the subsequent activation of downstream signalling molecules ERK1/2 and Akt. Paraffin-embedded tumour tissue was available from 98 patients with NETs (39 foregut, 42 midgut, four hindgut, five paragangliomas, and four of unknown origin). Immunohistochemical evaluation was performed for the expression of EGFR, p-EGFR, p-Akt, and p-ERK1/2. Ninety-six percent of tumour samples were positive for EGFR expression; 63% were positive for activated EGFR; 76% were positive for activated Akt; and 96% were positive for activated ERK1/2. Importantly, the histological score for the activation of Akt and ERK1/2 correlated with the histological score for activated EGFR. These data provide a rationale for considering EGFR inhibitors in the treatment of NETs. Additionally, direct inhibition of Akt and ERK1/2 may provide further therapeutic options in the treatment of NETs in the future.     

DJ‐1 expression in glioblastomas shows positive correlation with p53 expression and negative correlation with epidermal growth factor receptor amplification

DJ‐1, a protein that promotes the action of multiple anti‐apoptotic/pro‐survival pathways, is expressed prominently in human reactive astrocytes and in many human cancers. Glioblastomas (GBMs) are the most common adult primary brain tumor, and most show either abnormalities in p53 or epidermal growth factor receptor (EGFR) amplification, but not both. In this retrospective study of 40 surgically resected GBMs, we compared the immunohistochemical intensity of DJ‐1 expression (based on blinded scoring by independent examiners) to these and other molecular factors associated with GBM oncogenesis. We report here that: (i) most of the GBMs that we studied expressed DJ‐1 protein at significant levels, and typically in a cytoplasmic, non‐nuclear fashion; (ii) DJ‐1 staining intensity varied directly with strong nuclear p53 expression (assessed by immunostaining); and (iii) DJ‐1 staining intensity varied inversely with EGFR amplification (assessed by fluorescent in situ hybridization). Since the anti‐apoptotic/pro‐survival actions of DJ‐1 have been clearly linked in in vitro systems to p53 and receptor tyrosine kinase (i.e. EGFR) pathways that are hypothesized to be critical to GBM genesis, these observations indicate that DJ‐1 expression may play a role in the biology of some types of GBMs. Therefore, given the new associations presented here between DJ‐1, p53 and EGFR amplification in GBMs, future investigations of these tumors should include an analysis of DJ‐1 to determine whether its expression pattern is important for tumor progression, prognosis and responsiveness to therapy.     

Levels of transforming growth factor alpha (TGF-a)in human cerebrospinal fluid

In this study, we investigated cerebrospinal fluid of patients with various neurologicalsymptoms for the presence of transforming growth factor alpha (TGF-a). 41 samples ofcerebrospinal fluid were collected by lumbar puncture performed routinely due to the clinicalsuspicion of neurological disease from 22 females (age 15–80 years, median 42 years) and from19 males (age 18–82 years, median 48 years). A highly sensitive and specific radioimmunoassaywas used to determine the concentration of TGF-a in the samples. The detection limit of the assaywas about 200 pg TGF-a. There was no cross-reactivity to human EGF. We showed CSF indeeddoes contain TGFa. As TGF-a was detected in all 41 samples investigated, this growth factorappears to be a constant component of CSF. The mean concentration was 5.5 ng TGF-a (S.D.±2.7 pg/ml, range 1.1 to 13.9 pg/ml). There was no significant correlation between TGF-aconcentration in CSF and age (r=−0.006) and there was no significant differencebetween females (mean 5.8±3.10 pg/ml) and males (mean 5.2±1.96 pg/ml). No diagnosis wasover represented in patients with TGF-a concentrations above or below 1 S. D. off the mean.However, highest concentrations of TGF-a were found in the group of patients with peripheralneurological sensory dysfunctions and polyneuropathy. We conclude that TGF-a is not only aconstant component of human cerebrospinal fluid in adults but could also be significantly involvedin the pathophysiology of various neurological diseases. The earlier hypothesis that TGF-a couldmainly have a role in brain development needs hence to be re-evaluated.     

Immunological determinants of nerve growth factor involved in p140trk (Trk) receptor binding

Monoclonal anti-NGF antibodies that specifically inhibit the biological activity of mouse β-NGF were used to study the structural determinants involved in the interaction of NGF with its receptors gp75^LNGFR and Trk. None of the three antibodies–N60, M15, and 27/21–showed any reactivity toward denatured NGF. Three experimental methods–radioim-munoassay (RIA), enzyme-linked immunoassay (ELISA), and slot blots–detected no significant cross reactivity between the antibodies and BDNF or NT-3. RIA showed that M15 and N60 recognize the same or an overlapping antigenic site, but 27/21 recognizes a different epitope. Only 27/21, and not N60 or M15, immunoprecipitated β-NGF crosslinked to LNGFR receptor. Thus, the epitope recognized by 27/12 does not overlap the LNGFR receptor binding site. N60, M15, and 27/21 all block binding of NGF to Trk in a manner consistent with competitive inhibition. Purified Fab fragments of N60 and M15 gave similar results to the intact antibodies. The other subunits present in the 7S complex of NGF, i.e. the α and γ subunits, competitively inhibited binding of antibodies to β-NGF. Only the γ subunit inhibited phosphorylation of Trk and biological activity of β-NGF. These findings suggest that the M15, N60, and 27/21 antibodies bind to a specific site on the surface of NGF where they competitively inhibit binding to the Trk NGF receptor. The region encompassing the N-terminus, the C-terminus, and the loop on the surface of β-NGF containing residues 60–80 is proposed as important for binding to the Trk receptoe. © 1994 Wiley-Liss, Inc.     

PDGF-B及其受体蛋白在缺血大鼠脑组织中的表达

目的 探讨血小板源性生长因子B链(PDGF—B)及其受体PDGFR—β在缺血性脑损伤后濒危神经元存活和损伤修复中的作用。方法 采用线栓法制备大鼠大脑中动脉局灶性缺血模型，分别于缺血2h再灌注6h、24h、3d、7d、14d和21d处死，用免疫组化分别检测PDGF—B和PDGFR—β蛋白在脑缺血区及其周围的表达。结果 缺血再灌注后24h，PDGF—B和PDGFR—β在缺血区及其周围的神经元的表达开始增强，并分别于3d和7d出现第一个高峰，其中PDGFR—β的表达还可见于反应性胶质细胞；两者的第二个表达高峰出现在再灌注后14d，主要表达于梗死区增生的胶质细胞、新生血管和胶质疤痕周围的神经元。结论局灶性脑缺血后，PDGF—B及其受体蛋白在时间和空间上的一致性表达，说明它们对濒危神经元的存活、胶质疤痕形成和血管发生均有重要的作用。     

Weak association of the platelet-derived growth factor beta (PDGFB) and PDGF receptor beta (PDGFRB) genes with schizophrenia and schizoaffective disorder

Abstract

Schizophrenia is a severe neuropsychiatric disorder with diverse characterization of symptoms. Extensive research has been performed to elucidate the etiology of schizophrenia. One of the most convincing hypotheses comes from the dopaminergic system although none of the core genes has been consistently positive in association studies. Objective. In this investigation, we explored the possibility that the genes for platelet-derived growth factor beta (PDGFB) and its receptor (PDGFRB) might play an important role in the development of schizophrenia based on previous reports pointing to their ability to interact with the dopamine D₂/D₄ and NMDA receptors as well as their role in neurite outgrowth. Methods. We investigated the association of variants around these genes with schizophrenia and schizoaffective disorder in 104 small nuclear families using the Sib-Transmission Disequilibrium Test (TDT-STDT). Furthermore, quantitative trait analysis using family-based association test was applied to determine possible association of age at onset (AAO). Results. Allele G in PDGFRB(rs758588) was associated with AAO (P=0.019). An over-transmission of allele T in PDGFB(rs130650) polymorphism (P=0.043) and an over-transmission of allele A in PDGFRB(rs6865659) polymorphism (P=0.046) were observed. Furthermore, the combined TDT-STDT yielded consistent results. Conclusion. Overall, PDGFB and PDGFRB genes might play a role in the etiology of schizophrenia.     

Reduction of nerve growth factor receptor immunoreactivity in ischaemic gerbil hippocampal CA1 neurons after treatment with L-threo-3,4-dihydroxyphenylserine (DOPS)

Abstract

Nerve growth factor (NGF) synthesis in cultured mouse L-M fibroblast and astroglial cells can be increased after the treatment with L-threo-3,4-dihydroxyphenylserine (DOPS). Since the increase of NGF is not blocked by the treatment with decarboxylase inhibitor, DOPS may have direct effect to increase the NGF content. NGF and its receptor (NGFR) are suggested to play an important role in the neuronal survival and regeneration under pathologic conditions. In this study, we studied a possible protective effect of DOPS against the hippocampal CA1 cell death after transient forebrain ischaemia in gerbils in relation to the change of NGFR immunoreactivity. We found that treatment with DOPS (300 mg kg^–1) in combination with a decarboxylase inhibitor (benserazide, 10 mg kg^–1) protected ischaemic hippocampal CA1 cell against delayed neuronal death (neuronal density = 125 ± 24 mm^–1) as compared to the treatment with vehicle (49 ± 11 mm^–1) (p < 0.01). The immunoreactivity for NGFR was scarcely present in the sham-control CA1 area but was induced from 1 h and markedly expressed at 7 days after recirculation in the vehicle group. However; it was slightly and transiently induced from 8 h to 2 days in the DOPS plus benserazide treated group. These data suggest that the protective role of DOPS on the ischaemic hippocampal CA1 cells may act through the NGF and its receptor system. [Neurol Res 1994; 16: 201–204]     

Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas

gabctgPrognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas
Since glioblastomas in adults are uniformly fatal, evaluation of easily reproducible prognostic criteria which would attempt to define groups of patients is required. However, there is lack of a clear consensus regarding the expression of some markers in the literature. Therefore, an immunohistochemical study was performed to determine the prognostic significance of Ki67, p53, and epidermal growth factor receptor (EGFR) in a retrospective series of 63 glioblastomas. Image analysis was carried out in positive specimens to quantify the immunoprecipitates. p53 and EGFR expression were specifically addressed in the 36 primary glioblastomas reported in this series. In all cases, clinical data (age, Karnofsky performance scale index [KPS] before surgery, extent of surgery) and immunohistochemical features were analysed using univariate and multivariate analysis to ascertain whether any significant correlation exists between [1] EGFR expression [2], p53 accumulation [3], Ki67 labelling index and prognosis (survival time and disease-free survival time, DFST). The results showed that in this series of glioblastomas, none of these markers had any prognostic value. Among the clinical parameters, a high KPS before surgery was found to be indicative of a shorter DFST and survival time ( P <0.05), whereas a younger age at onset and total or subtotal surgical excision were associated with a longer survival ( P <0.001 and 0.05, respectively). EGFR protein accumulation was inversely correlated with p53 accumulation ( P =0.01). The percentage of the primary glioblastomas expressing EGFR was much lower in our study (33%) than in the literature suggesting that the molecular distinction between primary and secondary glioblastomas is not so clear-cut.     

The role of fibroblast growth factor receptor 4 polymorphisms in the susceptibility and clinical features of ischemic stroke

Some polymorphisms in the fibroblast growth factor receptor 4 gene (FGFR-4) have been correlated with coronary artery disease, however, the role of polymorphisms in the FGFR-4 gene in ischemic stroke remain unknown. A total of 270 patients with ischemic stroke and 297 controls were recruited. Stroke subtype was classified and clinical severity of stroke in patients was evaluated. The polymorphisms in the FGFR-4 were genotyped. There were no significant differences of genotype distributions and allele frequencies of rs145302848C/G and rs147603016G/A between stroke patients and controls (all p > 0.05). However, genotype frequencies and allele frequencies at rs351855G/A (Gly388Arg) were significantly different between stroke patients and controls (both p < 0.001). With the rs351855GG genotype as a reference, the presence of rs351855AA homozygote had a significantly increased risk for stroke (adjusted odds ratio 2.663; 95% confidence interval 1.673–4.229, p < 0.001). The polymorphisms at rs145302848C/G and rs147603016G/A did not influence the susceptibility of stroke in this study. All FGFR-4 polymorphisms were not associated with clinical features such as Trial of Org 10172 in Acute Stroke Treatment subtype or stroke severity as indicated by mean National Institutes of Health Stroke Scale scores. Our study suggests a positive association between FGFR-4 gene polymorphism at rs351855G/A and susceptibility to ischemic stroke.     

神经上皮组织起源的脑肿瘤增殖活性与表皮生长因子受体基因表达的相关性研究

目的　探讨表皮生长因子受体 (EGFR)基因表达与神经上皮组织起源的脑肿瘤增殖活性的关系。　　方法　利用EGFR和Ki-67单抗免疫组化染色及核仁组成区嗜银蛋白 (AgNOR)染色对8例正常脑组织、50例神经上皮组织起源的脑肿瘤和 4个恶性脑肿瘤体外细胞系进行检测。　　结果　神经上皮组织起源的脑肿瘤中EGFR蛋白表达阳性率为 54% ,WHO分级与EGFR蛋白表达呈正相关 (r =0 5597,P <0 0 1 )。Ki-67标记指数 (Ki-67LI)及AgNOR平均数均与神经上皮组织起源的脑肿瘤的分级有明显关系 (r分别为 0 8971和 0 880 1 ,P <0 0 1 ) ,且Ki-67LI与Ag NOR平均数有显著相关性 (r=0 9896,P <0 0 1 )。EGFR蛋白表达阳性的肿瘤组织及细胞系中高Ki-67LI及高AgNOR平均数者占 64 5% ,而无EGFR蛋白表达的肿瘤组织和正常脑组织中高Ki-67LI及高AgNOR平均数者仅为 2 2 6% ,二者间差别有统计学意义 (P <0 0 1 )。　　 结论　神经上皮组织起源的脑肿瘤中EGFR表达与细胞的分裂增殖活动密切相关